Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $10.80.

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th.

Regulus Therapeutics Stock Down 1.8 %

RGLS stock opened at $1.61 on Friday. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79. The stock’s 50 day moving average is $1.52 and its 200-day moving average is $1.74. The firm has a market capitalization of $105.46 million, a PE ratio of -1.50 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, equities research analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Regulus Therapeutics

A number of large investors have recently bought and sold shares of the company. Barclays PLC increased its position in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares during the last quarter. Jane Street Group LLC purchased a new stake in Regulus Therapeutics in the third quarter worth $46,000. State Street Corp increased its position in Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 33,496 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Regulus Therapeutics in the third quarter worth $1,403,000. Finally, NEA Management Company LLC purchased a new stake in Regulus Therapeutics in the third quarter worth $10,154,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.